Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B

[1]  R. Colonno,et al.  Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. , 2008, Journal of hepatology.

[2]  A. Lok,et al.  Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. , 2007, Gastroenterology.

[3]  E. Keeffe,et al.  Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  Yoshiyuki Suzuki,et al.  Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[5]  A. Cross,et al.  [781] FOUR YEAR ASSESSMENT OF ETV RESISTANCE IN NUCLEOSIDE-NAIVE AND LAMIVUDINE REFRACTORY PATIENTS , 2007 .

[6]  J. Villeneuve,et al.  Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. , 2007, Journal of hepatology.

[7]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[8]  C. Mazzucco,et al.  Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present , 2006, Antimicrobial Agents and Chemotherapy.

[9]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[10]  C. Mazzucco,et al.  Entecavir resistance is rare in nucleoside naïve patients with hepatitis B , 2006, Hepatology.

[11]  E. Schiff,et al.  A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[13]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[14]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[15]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[16]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[17]  P. Cane,et al.  Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. , 2004, Journal of hepatology.

[18]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[19]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[20]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[21]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  H. Kumada,et al.  [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[23]  R. Schinazi,et al.  The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. , 2001, The Journal of clinical investigation.

[24]  Ally,et al.  A ONE-YEAR TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS B , 2000 .

[25]  C. Chu,et al.  Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy , 1999, Hepatology.

[26]  E. Stelzl,et al.  Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. , 1998, Clinical and diagnostic virology.

[27]  Takao Tsuji,et al.  New Inuyama classification; new criteria for histological assessment of chronic hepatitis , 1996 .

[28]  R. Beasley.  Hepatitis B virus. The major etiology of hepatocellular carcinoma , 1988, Cancer.

[29]  P. Tiollais,et al.  Hepatitis B virus. , 1991, Scientific American.